Merck KGaA, Darmstadt, Germany: Lung Neoplasms trials

The registry lists 20 Lung Neoplasms studies with Merck KGaA, Darmstadt, Germany as lead sponsor. 0 are open to participants now and 14 have results posted.

Phase 1 8Phase 2 7Phase 3 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Bintrafusp Alfa Program Rollover StudyCompletedNCT05061823Phase 3Results posted
• Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)CompletedNCT04768296Phase 2Results posted
• M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)CompletedNCT03840915Phase 1/2Results posted
• M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)TerminatedNCT03840902Phase 2Results posted
• M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT03631706Phase 3Results posted
• Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)CompletedNCT02395172Phase 3Results posted
• Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian PopulationTerminatedNCT01015443Phase 3Results posted
• Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary ChemoradiotherapyCompletedNCT00960115Phase 1/2Results posted
• Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)CompletedNCT00820755Phase 3Results posted
• Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)CompletedNCT00409188Phase 3Results posted
• Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)CompletedNCT00157209Phase 2Results posted
• Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III DiseaseCompletedNCT00157196Phase 2Results posted
• Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)CompletedNCT00148798Phase 3Results posted
• Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung CancerCompletedNCT00111839Phase 2Results posted
• Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)TerminatedNCT03116971Phase 1
• Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung CancerWithdrawnNCT01731587Phase 1
• EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC)CompletedNCT00879866Phase 1
• Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLCCompletedNCT00633529Phase 1
• EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given CyclophosphamideCompletedNCT00132522Phase 1
• Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous TreatmentCompletedNCT00016237Phase 1